Longevity & AgingResearch PaperOpen Access

Correction Fixes Funding and Contact Details for HUC-MSC Aging Frailty Immunity Paper

A Frontiers in Immunology correction fixes the funding statement and author emails for a paper on stem cell therapy and immunity in frailty. It has no new data.

Friday, October 30, 2026 0 views
Published in Front Immunol
A journal editor's desk with a marked-up manuscript, a highlighted funding statement, and a faint stem cell illustration in the background

Summary

This item is a correction notice, not a research report. Published in Frontiers in Immunology in 2026, it amends an earlier paper on human umbilical cord mesenchymal stem cell (HUC-MSC) therapy and immune function in aging frailty. The notice replaces an incorrect funding statement, names the Shanghai "Rising Stars of Medical Talents" Youth Development Program as the correct funder, and lists the full set of grants supporting the work. It also fixes the corresponding-author emails, which now list Zhongmin Liu, Hua Jiang and Hailiang Liu at Tongji University. The correction contains no data, methods, or results, so it offers no new evidence on whether HUC-MSCs improve immunity or frailty. Readers who want scientific conclusions should consult the original article. The notice matters mainly for transparency, accurate funding attribution, and correct author contact details.

Detailed Summary

Corrections like this one are a routine part of scientific publishing. They keep funding disclosures and author contact information accurate, which matters for transparency and for tracing potential conflicts of interest. This notice relates to a paper on human umbilical cord mesenchymal stem cell (HUC-MSC) therapy and its effects on adaptive and innate immunity in aging frailty. The notice itself contains no scientific content.

The correction has two parts. First, the original funding statement was wrong. The correct funder is the Shanghai "Rising Stars of Medical Talents" Youth Development Program (Youth Medical Talents, General Practitioner Program). The corrected statement also lists the other funders: the Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai (Stem Cells and Translation), the National Natural Science Foundation of China, the Fundamental Research Funds for the Central Universities, the Natural Science Foundation of Shanghai, the Tongji University Medicine-X Interdisciplinary Research Initiative, and the National Key Research and Development Program of China.

Second, the correspondence emails for Zhongmin Liu and Hailiang Liu were incorrect. The corrected list gives three corresponding authors, Zhongmin Liu, Hua Jiang and Hailiang Liu, all with Tongji University addresses. The journal states that the original article has been updated to reflect both changes.

The notice has no study design, participants, outcomes, or conclusions. It cannot tell us whether HUC-MSC therapy restores immune function, reduces frailty, or is safe in older adults. Any such conclusions must come from the original paper, which should be read directly and judged on its own methods, including sample size, controls, and whether the findings are preclinical or clinical.

For readers, the main practical point is that the funding record and author contact details for the original paper have changed, so anyone citing or following up on that work should use the corrected version. Nothing in this notice suggests that the original scientific findings were altered or retracted.

Key Findings

  • The notice corrects the funding statement, naming the Shanghai "Rising Stars of Medical Talents" Youth Development Program as the correct funder.
  • The corrected statement lists seven further funding sources, including the National Natural Science Foundation of China and the National Key R&D Program.
  • Corresponding-author emails were corrected to list Zhongmin Liu, Hua Jiang and Hailiang Liu, all at Tongji University.
  • The notice contains no data, methods, or results and does not change or retract the original scientific findings.
  • The original article has been updated with the corrected information.

Methodology

This is an editorial correction, not a study. It has no experimental design, cohort, or analysis. It amends the funding statement and corresponding-author emails of a previously published paper on HUC-MSC therapy and immunity in aging frailty.

Study Limitations

The notice contains no scientific findings, so nothing about HUC-MSC therapy, immune function, or frailty can be evaluated from it. The original paper's methods and results are not described here, so any assessment of its quality requires reading the full article.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: